Your browser doesn't support javascript.
A Novel Y-Shaped, S-O-N-O-S-Bridged Cross-Link between Three Residues C22, C44, and K61 Is Frequently Observed in the SARS-CoV-2 Main Protease.
Yang, Kai S; Blankenship, Lauren R; Kuo, Syuan-Ting Alex; Sheng, Yan J; Li, Pingwei; Fierke, Carol A; Russell, David H; Yan, Xin; Xu, Shiqing; Liu, Wenshe Ray.
  • Fierke CA; Department of Biochemistry, Brandeis University, Waltham, Massachusetts 02453, United States.
  • Liu WR; Institute of Biosciences and Technology and Department of Translational Medical Sciences, College of Medicine, Texas A&M University, Houston, Texas 77030, United States.
ACS Chem Biol ; 18(3): 449-455, 2023 03 17.
Article in English | MEDLINE | ID: covidwho-2185505
ABSTRACT
As the COVID-19 pathogen, SARS-CoV-2 relies on its main protease (MPro) for pathogenesis and replication. During crystallographic analyses of MPro crystals that were exposed to the air, a uniquely Y-shaped, S-O-N-O-S-bridged post-translational cross-link that connects three residues C22, C44, and K61 at their side chains was frequently observed. As a novel covalent modification, this cross-link serves potentially as a redox switch to regulate the catalytic activity of MPro, a demonstrated drug target of COVID-19. The formation of this linkage leads to a much more open active site that can potentially be targeted for the development of novel SARS-CoV-2 antivirals. The structural rearrangement of MPro by this cross-link indicates that small molecules that lock MPro in the cross-linked form can potentially be used with other active-site-targeting molecules such as paxlovid for synergistic effects in inhibiting SARS-CoV-2 viral replication.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Randomized controlled trials Limits: Humans Language: English Journal: ACS Chem Biol Year: 2023 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Randomized controlled trials Limits: Humans Language: English Journal: ACS Chem Biol Year: 2023 Document Type: Article